| MURÍNOVÁ, Irena, Martin SVIDRNOCH, Tomas GUCKY, David REZAC, Jan HLAVAC, Ondrej SLANAR a Martin SIMA. Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. London: BMJ Publishing Group, 2022, Neuveden., October, s. 1-10. ISSN 2047-9956. Dostupné z: https://dx.doi.org/10.1136/ejhpharm-2022-003535. |
Další formáty:
BibTeX
LaTeX
RIS
@article{2237780,
author = {Murínová, Irena and Svidrnoch, Martin and Gucky, Tomas and Rezac, David and Hlavac, Jan and Slanar, Ondrej and Sima, Martin},
article_location = {London},
article_number = {October},
doi = {http://dx.doi.org/10.1136/ejhpharm-2022-003535},
keywords = {critical care; administration; intravenous; drug monitoring; pharmacy service; hospital; practice guideline},
language = {eng},
issn = {2047-9956},
journal = {EUROPEAN JOURNAL OF HOSPITAL PHARMACY},
title = {Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection},
url = {https://ejhp.bmj.com/content/early/2022/10/28/ejhpharm-2022-003535},
volume = {Neuveden.},
year = {2022}
}
TY - JOUR
ID - 2237780
AU - Murínová, Irena - Svidrnoch, Martin - Gucky, Tomas - Rezac, David - Hlavac, Jan - Slanar, Ondrej - Sima, Martin
PY - 2022
TI - Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection
JF - EUROPEAN JOURNAL OF HOSPITAL PHARMACY
VL - Neuveden.
IS - October
SP - 1-10
EP - 1-10
PB - BMJ Publishing Group
SN - 20479956
KW - critical care
KW - administration
KW - intravenous
KW - drug monitoring
KW - pharmacy service
KW - hospital
KW - practice guideline
UR - https://ejhp.bmj.com/content/early/2022/10/28/ejhpharm-2022-003535
N2 - Objectives The objective of this study was to develop a population pharmacokinetic model of meropenem in a heterogeneous population of patients with a serious bacterial infection in order to propose dosing optimisation leading to improved achievement of the pharmacokinetic/pharmacodynamic (PK/PD) target. Methods A total of 174 meropenem serum levels obtained from 144 patients during therapeutic drug monitoring were analysed using a non-linear mixed-effects modelling approach and Monte Carlo simulation was then used to compare various dosing regimens in order to optimise PK/PD target attainment. Results The meropenem volume of distribution of the patient population was 54.95 L, while clearance started at 3.27 L/hour and increased by 0.91 L/hour with each 1 mL/s/1.73 m2 of estimated glomerular filtration rate. Meropenem clearance was also 0.31 L/hour higher in postoperative patients with central nervous system infection. Meropenem administration by continuous infusion showed a significantly higher probability of attaining the PK/PD target than a standard 30 min infusion (95.3% vs 49.5%). Conclusions A daily meropenem dose of 3 g, 6 g and 10.5 g administered by continuous infusion was shown to be accurate for patients with moderate to severe renal impairment, normal renal function to mild renal impairment and augmented renal clearance, respectively
ER -
MURÍNOVÁ, Irena, Martin SVIDRNOCH, Tomas GUCKY, David REZAC, Jan HLAVAC, Ondrej SLANAR a Martin SIMA. Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection. \textit{EUROPEAN JOURNAL OF HOSPITAL PHARMACY}. London: BMJ Publishing Group, 2022, Neuveden., October, s.~1-10. ISSN~2047-9956. Dostupné z: https://dx.doi.org/10.1136/ejhpharm-2022-003535.
|
